Ray, S;
Jones, R;
Pritchard-Jones, K;
Dzhuma, K;
van den Heuvel-Eibrink, M;
Tytgat, G;
van der Beek, J;
... Murphy, D; + view all
(2020)
Pediatric and young adult renal cell carcinoma.
Pediatric Blood & Cancer
, 67
(11)
, Article e28675. 10.1002/pbc.28675.
Preview |
Text
Figure 1 flow chart.pdf - Accepted Version Download (260kB) | Preview |
Preview |
Text
Supporting Info Figure S1.pdf - Accepted Version Download (99kB) | Preview |
Preview |
Text
Pritchard-Jones_PBC Final Submission 11th August.pdf - Accepted Version Download (470kB) | Preview |
Preview |
Text
Pritchard-Jones_Table 1 pt characteristicsDOCX.pdf - Accepted Version Download (550kB) | Preview |
Preview |
Text
Pritchard-Jones_Supporting Info Table S1.pdf - Accepted Version Download (369kB) | Preview |
Preview |
Text
Pritchard-Jones_Supporting Figure S2 DOCX.pdf - Accepted Version Download (495kB) | Preview |
Abstract
Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine.
| Type: | Article |
|---|---|
| Title: | Pediatric and young adult renal cell carcinoma |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/pbc.28675 |
| Publisher version: | https://doi.org/10.1002/pbc.28675 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology, Hematology, Pediatrics, pediatrics, renal cell carcinoma, targeted therapy, treatment, NEPHRON-SPARING SURGERY, LYMPH-NODE INVOLVEMENT, OPEN-LABEL, RECOMBINANT INTERLEUKIN-2, RANDOMIZED PHASE-3, COMPLETE RESPONSE, CHILDREN, THERAPY, TUMORS, EVEROLIMUS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10113058 |
Archive Staff Only
 |
View Item |
